This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ramphal, R Articles by Kramer, B S Search for Related Content PubMed PubMed Citation Articles by Ramphal, R Articles by Kramer, B S

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1992 May; 36(5): 1062-1067

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study.

R Ramphal, M Bolger, D J Oblon, R J Sherertz, J D Malone, K H Rand, M Gilliom, J W Shands Jr and B S Kramer

Department of Medicine, University of Florida, Gainesville 32610-0277.

ABSTRACT

The use of vancomycin as part of the initial antibiotic therapy of febrile neutropenic patients has become a controversial issue. Some studies support its incorporation in the initial regimen, and others suggest that vancomycin can be added later. We examined this issue in a prospective, randomized trial. We randomized 127 febrile neutropenic patients to receive either ceftazidime alone or ceftazidime plus vancomycin as the initial empiric antibiotic treatment. We added vancomycin to the ceftazidime arm of the study when fever persisted after 96 h of monotherapy, when new fever occurred after this time, or when a moderately ceftazidime-resistant gram-positive bacterium was isolated. Each of these regimens had similar initial response rates, similar durations of initial fever, similar frequencies of new fever during therapy, similar microbiological cure rates, similar superinfection rates, and similar survival rates. We observed more renal and cutaneous toxicities in patients receiving vancomycin and ceftazidime as initial therapy. We conclude that ceftazidime is appropriate as initial therapy for febrile neutropenic patients and that the addition of vancomycin is appropriate when fever persists after 4 days of monotherapy or when fever recurs following an initial response.

---

Antimicrob Agents Chemother. 1992 May; 36(5): 1062-1067

This article has been cited by other articles:

• Paul, M., Borok, S., Fraser, A., Vidal, L., Leibovici, L. (2005). Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 55: 436-444 [Abstract] [Full Text]  
• Kim, S.-H., Park, W.-B., Lee, K.-D., Kang, C.-I., Bang, J.-W., Kim, H.-B., Kim, E.-C., Oh, M.-d., Choe, K.-W. (2004). Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 54: 489-497 [Abstract] [Full Text]  
• Nichols, W. G. (2003). Management of Infectious Complications in the Hematopoietic Stem Cell Transplant Recipient. J Intensive Care Med 18: 295-312 [Abstract]  
• Feld, R., DePauw, B., Berman, S., Keating, A., Ho, W. (2000). Meropenem Versus Ceftazidime in the Treatment of Cancer Patients With Febrile Neutropenia: A Randomized, Double-Blind Trial. JCO 18: 3690-3698 [Abstract] [Full Text]  
• Erjavec, Z., de Vries-Hospers, H. G., Laseur, M., Halie, R. M., Daenen, S. (2000). A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 45: 843-849 [Abstract] [Full Text]  
• Spera, R. V. Jr, Farber, B. F. (1992). Multiply-Resistant Enterococcus faecium: The Nosocomial Pathogen of the 1990s. JAMA 268: 2563-2564 [Abstract]